Original Research

Reliability of Biopsy Margin Status for Basal Cell Carcinoma: A Retrospective Study

Author and Disclosure Information

The reporting of biopsy margin status for basal cell carcinoma (BCC) varies among dermatopathologists. For biopsy specimens with seemingly negative margins, the question arises if the tumor extends beyond the margin in unexamined sections. We sought to determine the reliability of negative margin status for BCC and identify if any factors were predictive of positive true margins. We examined BCC biopsy specimens initially determined to have negative margins after routine sectioning and re-evaluated the margin status after complete tissue block sectioning of the initial biopsy specimen was performed. Our findings remind clinicians of the limitations of margin assessment and provide impetus for dermatopathologists to consider modifying how margin status is reported.

Practice Points

  • Clinicians must recognize the limitations of margin assessment of biopsy specimens and not rely on margin status to dictate treatment.
  • Dermatopathologists should consider modifying how margin status is reported, either by omitting it or clarifying its limitations on the pathology report.


 

References

Basal cell carcinoma (BCC) is the most common type of skin cancer frequently encountered in both dermatology and primary care settings.1 When biopsies of these neoplasms are performed to confirm the diagnosis, pathology reports may indicate positive or negative margin status. No guidelines exist for reporting biopsy margin status for BCC, resulting in varied reporting practices among dermatopathologists. Furthermore, the terminology used to describe margin status can be ambiguous and differs among pathologists; language such as “approaches the margin” or “margins appear free” may be used, with nonuniform interpretation between pathologists and providers, leading to variability in patient management.2

When interpreting a negative margin status on a pathology report, one must question if the BCC extends beyond the margin in unexamined sections of the specimen, which could be the result of an irregular tumor growth pattern or tissue processing. It has been estimated that less than 2% of the peripheral surgical margin is ultimately examined when serial cross-sections are prepared histologically (the bread loaf technique). However, this estimation would depend on several variables, including the number and thickness of sections and the amount of tissue discarded during processing.3 Importantly, reports of a false-negative margin could lead both the clinician and patient to believe that the neoplasm has been completely removed, which could have serious consequences.

Our study sought to determine the reliability of negative biopsy margin status for BCC. We examined BCC biopsy specimens initially determined to have uninvolved margins on routine tissue processing and determined the proportion with truly negative margins after complete tissue block sectioning of the initial biopsy specimen. We felt this technique was a more accurate measurement of true margin status than examination of a re-excision specimen. We also identified any factors that were predictive of positive true margins.

Methods

We conducted a retrospective study evaluating tissue samples collected at Geisinger Health System (Danville, Pennsylvania) from January to December 2016. Specimens were queried via the electronic database system at our institution (CoPath). We included BCC biopsy specimens with negative histologic margins on initial assessment that subsequently had block exhaust levels routinely ordered. These levels are cut every 100 to 150 µm, generating approximately 8 glass slides. We excluded all tumors that did not fit these criteria as well as those in patients younger than 18 years. Data collection was performed utilizing specimen pathology reports in addition to the note from the corresponding clinician office visit from the institution’s electronic medical record (Epic). Appropriate statistical calculations were performed. This study was approved by an institutional review board at our institution, which is required for all research involving human participants. This served to ensure the proper review and storage of patients’ protected health information.

Pages

Recommended Reading

FDA updates hydrochlorothiazide label to include nonmelanoma skin cancer risk
MDedge Dermatology
Large study finds no link between TCI use, skin cancer in patients with AD
MDedge Dermatology
Field Cancerization With Multiple Keratoacanthomas Successfully Treated With Topical and Intralesional 5-Fluorouracil
MDedge Dermatology
Cutaneous Odontogenic Sinus: An Inflammatory Mimicker of Squamous Cell Carcinoma and Epidermal Cysts
MDedge Dermatology
Intraoperative Tissue Expansion to Allow Primary Linear Closure of 2 Large Adjacent Surgical Defects
MDedge Dermatology
Nail Unit Squamous Cell Carcinoma: Updates on Diagnosis, Surgical Approach, and the Use of Mohs Micrographic Surgery
MDedge Dermatology
For SCC, legs are a high-risk anatomic site in women
MDedge Dermatology
Sunscreen myths, controversies continue
MDedge Dermatology
Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia
MDedge Dermatology
Daily sunscreen use will prevent more melanoma deaths than early detection
MDedge Dermatology